593 related articles for article (PubMed ID: 10421617)
1. Potent inhibition of the cytochrome P-450 3A-mediated human liver microsomal metabolism of a novel HIV protease inhibitor by ritonavir: A positive drug-drug interaction.
Kumar GN; Dykstra J; Roberts EM; Jayanti VK; Hickman D; Uchic J; Yao Y; Surber B; Thomas S; Granneman GR
Drug Metab Dispos; 1999 Aug; 27(8):902-8. PubMed ID: 10421617
[TBL] [Abstract][Full Text] [Related]
2. Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes.
Kumar GN; Rodrigues AD; Buko AM; Denissen JF
J Pharmacol Exp Ther; 1996 Apr; 277(1):423-31. PubMed ID: 8613951
[TBL] [Abstract][Full Text] [Related]
3. Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A.
Ma B; Prueksaritanont T; Lin JH
Drug Metab Dispos; 2000 Feb; 28(2):125-30. PubMed ID: 10640508
[TBL] [Abstract][Full Text] [Related]
4. Alprazolam-ritonavir interaction: implications for product labeling.
Greenblatt DJ; von Moltke LL; Harmatz JS; Durol AL; Daily JP; Graf JA; Mertzanis P; Hoffman JL; Shader RI
Clin Pharmacol Ther; 2000 Apr; 67(4):335-41. PubMed ID: 10801241
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of methadone and buprenorphine N-dealkylations by three HIV-1 protease inhibitors.
Iribarne C; Berthou F; Carlhant D; Dreano Y; Picart D; Lohezic F; Riche C
Drug Metab Dispos; 1998 Mar; 26(3):257-60. PubMed ID: 9492389
[TBL] [Abstract][Full Text] [Related]
6. Overlapping substrate specificities of cytochrome P450 3A and P-glycoprotein for a novel cysteine protease inhibitor.
Zhang Y; Guo X; Lin ET; Benet LZ
Drug Metab Dispos; 1998 Apr; 26(4):360-6. PubMed ID: 9531525
[TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo effects of the arylamine human immunodeficiency virus protease inhibitor 4R-(4alpha,5alpha,6beta, 7beta)-1-[(3-(1-imidazoylcarbamoyl)phenyl)methyl]-3-[(3-aminophenyl)m ethyl]hexahydro-5,6-dihydroxy-4,7-bis(phenylmethyl)-2H-1, 3-diazepin-2-one (SD894) on rat hepatic cytochrome P450 2B and 3A.
Grubb MF; Diamond S; Christ DD
Drug Metab Dispos; 1997 Dec; 25(12):1424-8. PubMed ID: 9394033
[TBL] [Abstract][Full Text] [Related]
8. Mechanism-based inactivation of CYP3A by HIV protease inhibitors.
Ernest CS; Hall SD; Jones DR
J Pharmacol Exp Ther; 2005 Feb; 312(2):583-91. PubMed ID: 15523003
[TBL] [Abstract][Full Text] [Related]
9. Oxidation of 1,8-cineole, the monoterpene cyclic ether originated from eucalyptus polybractea, by cytochrome P450 3A enzymes in rat and human liver microsomes.
Miyazawa M; Shindo M; Shimada T
Drug Metab Dispos; 2001 Feb; 29(2):200-5. PubMed ID: 11159812
[TBL] [Abstract][Full Text] [Related]
10. In vitro metabolism of the HIV-1 protease inhibitor ABT-378: species comparison and metabolite identification.
Kumar GN; Jayanti V; Lee RD; Whittern DN; Uchic J; Thomas S; Johnson P; Grabowski B; Sham H; Betebenner D; Kempf DJ; Denissen JF
Drug Metab Dispos; 1999 Jan; 27(1):86-91. PubMed ID: 9884314
[TBL] [Abstract][Full Text] [Related]
11. Metabolism of 7-benzyloxy-4-trifluoromethyl-coumarin by human hepatic cytochrome P450 isoforms.
Renwick AB; Surry D; Price RJ; Lake BG; Evans DC
Xenobiotica; 2000 Oct; 30(10):955-69. PubMed ID: 11315104
[TBL] [Abstract][Full Text] [Related]
12. Diltiazem inhibition of cytochrome P-450 3A activity is due to metabolite intermediate complex formation.
Jones DR; Gorski JC; Hamman MA; Mayhew BS; Rider S; Hall SD
J Pharmacol Exp Ther; 1999 Sep; 290(3):1116-25. PubMed ID: 10454485
[TBL] [Abstract][Full Text] [Related]
13. Identification of the human liver cytochrome P450 isoenzyme responsible for the 6-methylhydroxylation of the novel anticancer drug 5,6-dimethylxanthenone-4-acetic acid.
Zhou S; Paxton JW; Tingle MD; Kestell P
Drug Metab Dispos; 2000 Dec; 28(12):1449-56. PubMed ID: 11095582
[TBL] [Abstract][Full Text] [Related]
14. Effects of antidepressant drugs on the activity of cytochrome P-450 measured by caffeine oxidation in rat liver microsomes.
Danie WA; Syrek M; Ryłko Z; Wójcikowski J
Pol J Pharmacol; 2001; 53(4):351-7. PubMed ID: 11990081
[TBL] [Abstract][Full Text] [Related]
15. In vitro metabolism of simvastatin in humans [SBT]identification of metabolizing enzymes and effect of the drug on hepatic P450s.
Prueksaritanont T; Gorham LM; Ma B; Liu L; Yu X; Zhao JJ; Slaughter DE; Arison BH; Vyas KP
Drug Metab Dispos; 1997 Oct; 25(10):1191-9. PubMed ID: 9321523
[TBL] [Abstract][Full Text] [Related]
16. Stereoselective metabolism of cibenzoline, an antiarrhythmic drug, by human and rat liver microsomes: possible involvement of CYP2D and CYP3A.
Niwa T; Shiraga T; Mitani Y; Terakawa M; Tokuma Y; Kagayama A
Drug Metab Dispos; 2000 Sep; 28(9):1128-34. PubMed ID: 10950860
[TBL] [Abstract][Full Text] [Related]
17. Oxidative metabolism of monensin in rat liver microsomes and interactions with tiamulin and other chemotherapeutic agents: evidence for the involvement of cytochrome P-450 3A subfamily.
Nebbia C; Ceppa L; Dacasto M; Carletti M; Nachtmann C
Drug Metab Dispos; 1999 Sep; 27(9):1039-44. PubMed ID: 10460804
[TBL] [Abstract][Full Text] [Related]
18. Evidence for CYP3A-mediated N-deethylation of amiodarone in human liver microsomal fractions.
Fabre G; Julian B; Saint-Aubert B; Joyeux H; Berger Y
Drug Metab Dispos; 1993; 21(6):978-85. PubMed ID: 7905403
[TBL] [Abstract][Full Text] [Related]
19. Small intestinal metabolism of the 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor lovastatin and comparison with pravastatin.
Jacobsen W; Kirchner G; Hallensleben K; Mancinelli L; Deters M; Hackbarth I; Baner K; Benet LZ; Sewing KF; Christians U
J Pharmacol Exp Ther; 1999 Oct; 291(1):131-9. PubMed ID: 10490896
[TBL] [Abstract][Full Text] [Related]
20. The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fluvastatin: effect on human cytochrome P-450 and implications for metabolic drug interactions.
Fischer V; Johanson L; Heitz F; Tullman R; Graham E; Baldeck JP; Robinson WT
Drug Metab Dispos; 1999 Mar; 27(3):410-6. PubMed ID: 10064574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]